1. Home
  2. CTMX vs IKNA Comparison

CTMX vs IKNA Comparison

Compare CTMX & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • IKNA
  • Stock Information
  • Founded
  • CTMX 2008
  • IKNA 2016
  • Country
  • CTMX United States
  • IKNA United States
  • Employees
  • CTMX N/A
  • IKNA N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • IKNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTMX Health Care
  • IKNA Health Care
  • Exchange
  • CTMX Nasdaq
  • IKNA Nasdaq
  • Market Cap
  • CTMX 62.3M
  • IKNA 81.6M
  • IPO Year
  • CTMX 2015
  • IKNA 2021
  • Fundamental
  • Price
  • CTMX $0.80
  • IKNA $1.49
  • Analyst Decision
  • CTMX Buy
  • IKNA Buy
  • Analyst Count
  • CTMX 6
  • IKNA 2
  • Target Price
  • CTMX $5.77
  • IKNA $3.00
  • AVG Volume (30 Days)
  • CTMX 731.5K
  • IKNA 169.0K
  • Earning Date
  • CTMX 03-10-2025
  • IKNA 03-11-2025
  • Dividend Yield
  • CTMX N/A
  • IKNA N/A
  • EPS Growth
  • CTMX N/A
  • IKNA N/A
  • EPS
  • CTMX 0.16
  • IKNA N/A
  • Revenue
  • CTMX $126,617,000.00
  • IKNA $659,000.00
  • Revenue This Year
  • CTMX $22.55
  • IKNA N/A
  • Revenue Next Year
  • CTMX N/A
  • IKNA N/A
  • P/E Ratio
  • CTMX $4.93
  • IKNA N/A
  • Revenue Growth
  • CTMX 33.66
  • IKNA N/A
  • 52 Week Low
  • CTMX $0.75
  • IKNA $1.22
  • 52 Week High
  • CTMX $5.85
  • IKNA $1.94
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 41.61
  • IKNA 48.35
  • Support Level
  • CTMX $0.75
  • IKNA $1.40
  • Resistance Level
  • CTMX $0.98
  • IKNA $1.60
  • Average True Range (ATR)
  • CTMX 0.06
  • IKNA 0.07
  • MACD
  • CTMX 0.00
  • IKNA 0.01
  • Stochastic Oscillator
  • CTMX 20.13
  • IKNA 47.62

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Share on Social Networks: